Deutsch English Français

Contact

EP1621212

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1621212

EP1621212 - Formulations comprising antisense nucleotides to connexins [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 21.09.2012 Database last updated on 02.09.2024
Most recent event Tooltip	21.09.2012	No opposition filed within time limit	published on 24.10.2012 [2012/43]
Applicant(s)	For all designated states Coda Therapeutics, Inc. 10505 Sorrento Valley Road, Suite 395 San Diego, CA 92121 / US
	[2011/32]
Former [2006/05]	For all designated states Becker, David, Dr. 19 Lapwing Way, Abbots Langley Hertfordshire, WD5 0GG / GB
	For all designated states Green, Colin R., Dr. 3/4 Cresent Road Epsom, Auckland / NZ
Inventor(s)	01 / Becker David. Dr 19 Lapwing Way Abbots Langley Hertfordshire WD5 0GG / GB
	02 / Green Colin R. Dr 3/4 Cresent Road Epsom Auckland / NZ
	[2011/32]
Former [2006/05]	01 / see applicant ...
Representative(s)	Duckworth, Timothy John J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	[N/P]
Former [2011/46]	Duckworth, Timothy John J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB
Former [2006/05]	Duckworth, Timothy John J.A. Kemp & Co., 14 South Square, Gray's Inn London WC1R 5JJ / GB
Application number, filing date	05016736.0	27.01.2000
	[2006/05]
Priority number, date	NZ19990333928	27.01.1999 Original published format: NZ 33392899
	NZ19990500190	07.10.1999 Original published format: NZ 50019099
	[2006/05]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP1621212
	Date:	01.02.2006
	Language:	EN
	[2006/05]
	Type:	B1 Patent specification
	No.:	EP1621212
	Date:	16.11.2011
	Language:	EN
	[2011/46]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	19.12.2005
Classification	IPC:	A61K48/00, A61K31/70, C12N15/11, A61P17/02	[2006/05]
	CPC:	C12N15/111 (EP,US); C07H21/04 (US); A61K31/711 (EP,US); A61P17/00 (EP); A61P17/02 (EP); A61P17/12 (EP); (+) A61P17/16 (EP); A61P25/00 (EP); A61P29/00 (EP); A61P43/00 (EP); C12N15/1138 (EP,US); A61K38/00 (EP,US); C12N2310/11 (EP,US); C12N2320/32 (EP,US) (-)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2006/05]
Title	German:	Formulierungen enthaltend Antisense Nukleotide spezifisch für Connexine	[2006/05]
	English:	Formulations comprising antisense nucleotides to connexins	[2006/05]
	French:	Formulation comprenant des nucléotides antisens contre les connexines	[2006/05]
Examination procedure	01.08.2006	Examination requested [2006/37]
	30.08.2006	Despatch of a communication from the examining division (Time limit: M06)
	20.06.2007	Reply to a communication from the examining division
	25.01.2008	Despatch of a communication from the examining division (Time limit: M06)
	06.11.2008	Reply to a communication from the examining division
	13.09.2010	Cancellation of oral proceeding that was planned for 04.10.2010
	04.10.2010	Date of oral proceedings (cancelled)
	27.10.2010	Communication of intention to grant the patent
	11.04.2011	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
	20.06.2011	Fee for grant paid
	20.06.2011	Fee for publishing/printing paid
Parent application(s) Tooltip	EP00901236.0 / EP1146908
Divisional application(s)	EP10013180.4 / EP2314321
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000901236) is 17.01.2003
Opposition(s)	17.08.2012	No opposition filed within time limit [2012/43]
Request for further processing for:	The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
	20.06.2011	Request for further processing filed
	20.06.2011	Full payment received (date of receipt of payment) Request granted
	04.07.2011	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	06.11.2008	Request for further processing filed
	06.11.2008	Full payment received (date of receipt of payment) Request granted
	18.11.2008	Decision despatched
	20.06.2007	Request for further processing filed
	20.06.2007	Full payment received (date of receipt of payment) Request granted
	06.07.2007	Decision despatched
Fees paid	Renewal fee
	02.08.2005	Renewal fee patent year 03
	02.08.2005	Renewal fee patent year 04
	02.08.2005	Renewal fee patent year 05
	02.08.2005	Renewal fee patent year 06
	12.01.2006	Renewal fee patent year 07
	24.01.2007	Renewal fee patent year 08
	24.01.2008	Renewal fee patent year 09
	14.01.2009	Renewal fee patent year 10
	28.01.2010	Renewal fee patent year 11
	14.01.2011	Renewal fee patent year 12
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO9824797 (DYAD PHARMACEUTICAL CORP [US], et al) [A] 1-52 * see claims 1-22; abstract; page 3, lines 4-18; example 5 (pages 18-19) *;
		[XY] - RUCH R J ET AL, "Inhibition of gap junctional intercellular communication and enhancement of growth in BALB/c 3T3 cells treated with connexin43 antisense oligonucleotides.", MOLECULAR CARCINOGENESIS, (1995 DEC) 14 (4) 269-74., (1995), XP000909565 [X] 1,3,5,6,11,13,15,17,20,24-26,28-30,32,37,38 * see the abstract; page 270 (section "Treatment of cells with ODN' s); page 273, last paragraph * [Y] 1-52
		[XY] - BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, XP002138806 [X] 1,3,5,6,11,13,15,17,20,24-26,28-30,32,37,38 * abstract * [Y] 1-52
		[XY] - BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, XP002138807 [X] 1,3,5,6,11,13,15,17,20,24-26,28-30,32,37,38 * abstract * [Y] 1-52
		[XY] - DAVIS L M ET AL, "MODULATION OF CONNEXIN43 EXPRESSION: EFFECTS ON CELLULAR COUPLING", JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, FUTURA PUBLISHING CO., ARMONK, NY, US, (1995), vol. 6, no. 2, ISSN 1045-3873, pages 103 - 114, XP000909568 [X] 1,3,5,6,11,13,15,17,20,24-28,30,32,37,38 * abstract * * page 104, column R, paragraph 3 * Discussion [Y] 1-52
		[Y] - ROZENTAL R ET AL, "STABLE TRANSFECTION WITH CONNEXIN43 INHBITS NEURONAL DIFFERENTIATION OF PC12 CELLS", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, (19971025), vol. 23, no. 1-3, ISSN 0190-5295, page 22, XP009006429 [Y] 1-52 * the whole document *
		[A] - GOLIGER, JEFFREY A. ET AL, "Wounding alters epidermal connexin expression and gap junction-mediated intercellular communication", MOL. BIOL. CELL (1995), 6(11), 1491-501, (1995), XP000909594 [A] 1-52 * see the asbstract *
		[PX] - BECKER D L ET AL, "Connexin alpha1 and cell proliferation in the developing chick retina", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, (199904), vol. 156, no. 2, ISSN 0014-4886, pages 326 - 332, XP002347187 [PX] 1-52 * the whole document * DOI: http://dx.doi.org/10.1006/exnr.1999.7027
		[T] - GREEN C R ET AL, "Spatiotemporal Depletion of connexins Using Antisense Oligonucleotides", METHODS IN MOLECULAR BIOLOGY, HUMANA PRESS INC., CLIFTON, NJ, US, (2001), vol. 154, pages 175 - 185, XP008053224 [T] 1-52 * the whole document *
		[T] - FRANTSEVA M V ET AL, "Ischemia-induced brain damage depends on specific gap-junctional coupling", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, RAVEN PRESS, LTD., NEW YORK, NY, US, (200204), vol. 22, no. 4, ISSN 0271-678X, pages 453 - 462, XP008053227 [T] 1-52 DOI: http://dx.doi.org/10.1097/00004647-200204000-00009
		[ ] - MOORE ET AL., "Selective block of gap junction channel expression with connexin-specific antisense oligodeoxynucleotides", AM J PHYSIOLOGY, (1994), vol. 265, no. 1, pages C1371 - C1388, XP000909522 [ ] * table 1 *
		[ ] - GRAZUL-BILSKA ET AL., "Transfection of bovine luteal cells with gap junctional protein connexin 43 (Cx43) antisense oligonucleotide affects progesterone secretion", BIOLOGY REPRODUCTION, (1998), vol. 58, no. Supp 1, page 78, XP000909989

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p